monoclonal antibodies market Latest News

Driven by their target oriented nature that enables them to attack only the diseased cells without affecting the healthy ones, biopharmaceuticals today represent one of the fastest growing segments of the pharmaceutical industry.

Growing at a CAGR of around 17% during 2012-2014, the segment under blood clotting factor will provide a significant boost to the Global Protein Therapeutics Market, says RNCOS in its latest research study.

Sales of major insulin and insulin analogues brands is anticipated to grow at a CAGR of around 18% during 2012-2014, providing a boost to the global protein therapeutics market, says RNCOS in its latest research offering.

In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existing products, our latest study shows.

The global market for diagnostic and therapeutic market is expected to exceed $ 25 million market by the end of 2010. mAbs held the top 3 ranks among the top selling brands in 2008.

With the increasing number of diabetic patients and rising insulin demand from the emerging markets, the global insulin market will grow at a CAGR of 15% during 2010-2013, says RNCOS in its latest research study.

With increasing number of cancer patients and rising health insurance coverage, the global monoclonal antibodies market will hit a CAGR of 13% during 2010-2013, says a latest research report from RNCOS.

RNCOS has recently added a new Market Research Report titled, “Global Protein Therapeutics Market Analysis” to its report gallery. The report provides extensive information of the global protein therapeutics market.